Mycrodose Therapeutics to Discuss Advanced Drug Delivery Devices at Psychedelic Medicine Event

San Diego, California--(Newsfile Corp. - July 27, 2021) -  Mycrodose Therapeutics, a US-Based pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announced today that its Executive team will be participating in the upcoming Psychedelic Capital Event on July 29, 2021. 

The virtual conference hosted by Microdose Psychedelic Insights will enable Mycrodose Therapeutics the opportunity to present as a panel on the company’s core drug delivery systems, their major milestones & accomplishments, and the company’s outlook on the expanding psychedelic pharmaceutical sector.

“Mycrodose Therapeutics started from a deep personal need to find better solutions for treating mental health. We have a deep desire of improving the fight against the mental health pandemic that impacts all ages, all ethnicities, all genders, and spans the entire globe. Our continued mission is to develop cutting-edge technologies and novel IP in order to bring more happiness, love, connection, and understanding to those suffering. We look forward to sharing more at the Psychedelic Capital Event this week.” – Patrick Eckstrom, Chief Operating Officer.

Panel Topic: Advanced Drug Delivery of Psychedelic Compounds

Panel Presenters: Chad Conner, Chief Executive Officer; Frank Kochinke, Chief Science Officer; Patrick Eckstrom, Chief Operating Officer

Date: Thursday, July 29, 2021

Time:  10:30 AM PST (1:30 PM EST) – Introduction by Patrick Moher, CEO of Microdose Psychedelic Insights, and Richard Skaife, Co-Founder of The Conscious Fund. 

10:45 AM PST (1:45 PM EST) – Presentation by Mycrodose Therapeutics

Tickets: FREE Only Through This Link: https://microdose.buzz/discount/psycap/

About Mycrodose Therapeutics

Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds: Psilocybin, MDMA, DMT & LSD by the United States Drug Enforcement Agency (DEA). 

For more information about Mycrodose Therapeutics, please contact: 

Patrick Eckstrom
Chief Operating Officer
Mycrodose Therapeutics
Email: Patrick@MycrodoseThera.com
Phone: 1-619-494-1367
Website: www.MycrodoseThera.com